Phase 2
Completed N=13
Effect of Dalfampridine (4-AP) on Genioglossus Muscle Activity in Healthy Adults
Sleep Apnea, Obstructive
Source: ClinicalTrials.gov NCT02656160 ↗
Enrolled (actual)
13
Serious AEs
0.0%
Results posted
Jun 2017
Primary outcomePrimary: Genioglossus Activity During Sleep Expressed as %Wakefulness Value (Before Drug/Placebo Administration). — 166; 136; 245; 163 percentage of wakefulness value — p=0.85
Summary
In this protocol the investigators will test the effect of dalfampridine (a potassium channel blocker) on genioglossus muscle activity (EMG GG) during wakefulness and sleep in healthy control subjects.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Genioglossus Activity During Sleep Expressed as %Wakefulness Value (Before Drug/Placebo Administration). |
166; 136; 245; 163 | 0.85 |
| SECONDARY Change in EMG GG for cmH2O Change in Epiglottic Pressure. (GG%Max/cmH2O) |
-0.23; -0.36 | 0.42 |
Eligibility Criteria
Inclusion Criteria
- Healthy control subjects
Exclusion Criteria
- Cardiovascular disease other than well controlled hypertension
- History of seizures
Data sourced from ClinicalTrials.gov (NCT02656160). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.